scout
|Articles|February 1, 2008

Oncology NEWS International

  • Oncology NEWS International Vol 17 No 2
  • Volume 17
  • Issue 2

Exelixis/BMS to develop XL139, hedgehog pathway inhibitor

Exelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States.

SOUTH SAN FRANCISCO, California—Exelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States. Hedgehog plays a critical role in regulating cell growth, proliferation, and differentiation, and is deregulated in a variety of cancers, making it a promising target for cancer therapies, Exelixis said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.


Latest CME